Gene: SMYD3
Official Full Name: SET and MYND domain containing 3provided by HGNC
Gene Summary: This gene encodes a histone methyltransferase which functions in RNA polymerase II complexes by an interaction with a specific RNA helicase. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Dec 2011]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO20200 | SMYD3 Knockout cell line (HeLa) | Human | SMYD3 | 1:3~1:6 | Negative | Online Inquiry |
KO20201 | SMYD3 Knockout cell line (HCT 116) | Human | SMYD3 | 1:2~1:4 | Negative | Online Inquiry |
KO20202 | SMYD3 Knockout cell line (HEK293) | Human | SMYD3 | 1:3~1:6 | Negative | Online Inquiry |
KO20203 | SMYD3 Knockout cell line (A549) | Human | SMYD3 | 1:3~1:4 | Negative | Online Inquiry |
SMYD3 Gene Knockout Cell Lines are state-of-the-art biological tools engineered for the study of the SMYD3 gene, which encodes a histone methyltransferase implicated in various cellular processes, including gene regulation and oncogenesis. By creating knockout models in selected cell lines, researchers can observe the phenotypic outcomes of the absence of SMYD3, enabling comprehensive investigations into its biological roles and its potential as a therapeutic target.
These cell lines function by utilizing CRISPR/Cas9 technology to introduce targeted mutations in the SMYD3 gene, leading to a complete loss of its expression. This mechanism allows researchers to elucidate the downstream effects of SMYD3 activity, evaluate its interplay with other signaling pathways, and assess the impact on cellular behaviors, such as proliferation, differentiation, and apoptosis. The specificity of the knockout approach minimizes off-target effects, making the findings robust and reliable.
The scientific importance of SMYD3 Gene Knockout Cell Lines lies in their applications across cancer research, stem cell biology, and epigenetics. In clinical settings, understanding SMYD3's contributions to malignancy could indicate novel therapeutic strategies and prognostic markers, offering hope in developing targeted cancer treatments.
Compared to traditional methods, such as RNA interference or pharmacological inhibition, the SMYD3 Gene Knockout Cell Lines provide a more permanent and comprehensive loss-of-function model. This advantage leads to more accurate recapitulation of physiological and pathological states, significantly improving experimental outcomes.
For researchers and clinicians alike, these cell lines represent an invaluable resource for advancing our understanding of SMYD3. By elucidating its biological functions, users can harness this knowledge for impactful research and transformative clinical applications. Our company prides itself on its commitment to innovation and quality, delivering meticulously validated biological products that empower the scientific community to explore the complexities of genetics and disease.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.